MA43052B1 - Inhibiteurs de la kallicréine plasmatique humaine - Google Patents
Inhibiteurs de la kallicréine plasmatique humaineInfo
- Publication number
- MA43052B1 MA43052B1 MA43052A MA43052A MA43052B1 MA 43052 B1 MA43052 B1 MA 43052B1 MA 43052 A MA43052 A MA 43052A MA 43052 A MA43052 A MA 43052A MA 43052 B1 MA43052 B1 MA 43052B1
- Authority
- MA
- Morocco
- Prior art keywords
- plasma kallikrein
- human plasma
- kallikrein inhibitors
- compounds
- relates
- Prior art date
Links
- 229940127379 Kallikrein Inhibitors Drugs 0.000 title abstract 2
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000003827 Plasma Kallikrein Human genes 0.000 abstract 2
- 108090000113 Plasma Kallikrein Proteins 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
L'invention concerne des composés de la formule (i), et leurs sels pharmaceutiquement acceptables. Les composés sont des inhibiteurs de la kallicréine plasmatique. L'invention concerne également des compositions pharmaceutiques comprenant au moins un composé selon l'invention, et des méthodes impliquant l'utilisation des composés et des compositions selon l'invention pour le traitement et la prévention de maladies et de pathologies caractérisées par une activité indésirable de la kallicréine plasmatique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562235754P | 2015-10-01 | 2015-10-01 | |
PCT/US2016/054619 WO2017059178A1 (fr) | 2015-10-01 | 2016-09-30 | Inhibiteurs de la kallicréine plasmatique humaine |
Publications (2)
Publication Number | Publication Date |
---|---|
MA43052A MA43052A (fr) | 2021-05-12 |
MA43052B1 true MA43052B1 (fr) | 2021-11-30 |
Family
ID=58424336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA43052A MA43052B1 (fr) | 2015-10-01 | 2016-09-30 | Inhibiteurs de la kallicréine plasmatique humaine |
Country Status (31)
Country | Link |
---|---|
US (3) | US10562850B2 (fr) |
EP (2) | EP4019022B1 (fr) |
JP (2) | JP6916171B2 (fr) |
KR (1) | KR20180058815A (fr) |
CN (2) | CN108289893B (fr) |
AR (1) | AR106241A1 (fr) |
AU (2) | AU2016330926B2 (fr) |
CA (1) | CA2999164A1 (fr) |
CO (1) | CO2018004572A2 (fr) |
CY (1) | CY1124907T1 (fr) |
DK (2) | DK4019022T3 (fr) |
EA (2) | EA202191548A1 (fr) |
ES (1) | ES2905401T3 (fr) |
FI (1) | FI4019022T3 (fr) |
HK (1) | HK1254865A1 (fr) |
HR (1) | HRP20220059T1 (fr) |
HU (1) | HUE057106T2 (fr) |
IL (3) | IL291268B2 (fr) |
LT (2) | LT3355890T (fr) |
MA (1) | MA43052B1 (fr) |
MD (1) | MD3355890T2 (fr) |
MX (2) | MX2018003930A (fr) |
MY (1) | MY198346A (fr) |
PH (1) | PH12018500678A1 (fr) |
PL (1) | PL3355890T3 (fr) |
PT (2) | PT4019022T (fr) |
RS (1) | RS62807B1 (fr) |
SG (1) | SG10202003705WA (fr) |
SI (1) | SI3355890T1 (fr) |
TW (2) | TWI734702B (fr) |
WO (1) | WO2017059178A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA202191548A1 (ru) * | 2015-10-01 | 2021-09-02 | Байокрист Фармасьютикалз, Инк. | Ингибиторы плазменного калликреина человека |
CA3070717A1 (fr) * | 2017-08-04 | 2019-02-07 | Dyax Corp. | Inhibiteurs de la kallikreine plasmatique et utilisations associees |
JP2021535112A (ja) | 2018-08-20 | 2021-12-16 | アキリオン ファーマシューティカルズ,インコーポレーテッド | 補体d因子の医学的障害の治療のための医薬化合物 |
CN110938077B (zh) * | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | 合成Avapritinib的方法 |
TW202144331A (zh) * | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
CN116444485B (zh) * | 2023-03-30 | 2024-01-23 | 广西中医药大学 | 吡啶基取代不对称脲的非金属催化、免柱层析合成方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
WO1990013332A1 (fr) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Support pour medicaments a liberation progressive |
DE69110787T2 (de) | 1990-02-28 | 1996-04-04 | Medtronic Inc | Intraluminale prothese mit wirkstoffeluierung. |
US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
CA2170030A1 (fr) * | 1993-09-14 | 1995-03-23 | Robert A. Lazarus | Compositions pharmaceutiques renfermant de l'ecotine et leurs homologues |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
ES2189968T3 (es) * | 1996-08-16 | 2003-07-16 | Bristol Myers Squibb Pharma Co | Amidinofenil-pirrolidinas,-pirrolinas,e -isoxazolidinas y derivadOS DE LOS MISMOS. |
EP1217000A1 (fr) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibiteurs du factor Xa et factor VIIa |
PL204653B1 (pl) | 2001-09-21 | 2010-01-29 | Bristol Myers Squibb Co | Pochodna pirazolo [3, 4-c] pirydyny, jej zastosowanie i kompozycja farmaceutyczna |
US7030141B2 (en) * | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
DE10301300B4 (de) * | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
KR20050118708A (ko) * | 2003-04-03 | 2005-12-19 | 메르크 파텐트 게엠베하 | 혈전-색전 질환의 치료에서 응고 인자 xa의 저해제로서사용하기 위한피롤리디노-1,2-디카르복시-1-(페닐아미드)-2-(4-(3-옥소-모르폴리노-4-일)-페닐아미드) 유도체 및 관련화합물 |
DE10315377A1 (de) * | 2003-04-03 | 2004-10-14 | Merck Patent Gmbh | Carbonylverbindungen |
US7199149B2 (en) | 2003-10-01 | 2007-04-03 | Bristol Myers Squibb Company | Monocyclic and bicyclic lactams as factor Xa inhibitors |
DE102004014945A1 (de) * | 2004-03-26 | 2005-10-13 | Merck Patent Gmbh | Prolinylderivate |
TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之新穎巨環化合物 |
WO2013111107A1 (fr) | 2012-01-27 | 2013-08-01 | Novartis Ag | Dérivés d'aminopyridine utilisés en tant qu'inhibiteurs de la kallicréine plasmatique |
WO2013111108A1 (fr) | 2012-01-27 | 2013-08-01 | Novartis Ag | Dérivés hétéroarylcarboxamide à 5 chaînons comme inhibiteurs de la kallikréine plasmatique |
TWI570120B (zh) | 2012-06-04 | 2017-02-11 | 艾克泰聯製藥有限公司 | 苯并咪唑脯胺酸衍生物 |
GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
EP3095786A4 (fr) | 2014-01-14 | 2017-10-11 | Sumitomo Dainippon Pharma Co., Ltd. | Dérivé condensé de 5-oxazolidinone |
HUE060660T2 (hu) | 2014-03-07 | 2023-04-28 | Biocryst Pharm Inc | Szubsztituált pirazolok mint humán plazma kallikrein-gátlók |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
CN107405333A (zh) | 2015-02-27 | 2017-11-28 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
EA202191548A1 (ru) | 2015-10-01 | 2021-09-02 | Байокрист Фармасьютикалз, Инк. | Ингибиторы плазменного калликреина человека |
-
2016
- 2016-09-30 EA EA202191548A patent/EA202191548A1/ru unknown
- 2016-09-30 WO PCT/US2016/054619 patent/WO2017059178A1/fr active Application Filing
- 2016-09-30 DK DK21205884.6T patent/DK4019022T3/da active
- 2016-09-30 EP EP21205884.6A patent/EP4019022B1/fr active Active
- 2016-09-30 US US15/764,071 patent/US10562850B2/en active Active
- 2016-09-30 CA CA2999164A patent/CA2999164A1/fr active Pending
- 2016-09-30 EA EA201890862A patent/EA038492B1/ru unknown
- 2016-09-30 IL IL291268A patent/IL291268B2/en unknown
- 2016-09-30 KR KR1020187012013A patent/KR20180058815A/ko not_active Application Discontinuation
- 2016-09-30 PL PL16852664T patent/PL3355890T3/pl unknown
- 2016-09-30 FI FIEP21205884.6T patent/FI4019022T3/fi active
- 2016-09-30 SG SG10202003705WA patent/SG10202003705WA/en unknown
- 2016-09-30 TW TW105131766A patent/TWI734702B/zh active
- 2016-09-30 CN CN201680069679.7A patent/CN108289893B/zh active Active
- 2016-09-30 AR ARP160103021A patent/AR106241A1/es unknown
- 2016-09-30 JP JP2018516461A patent/JP6916171B2/ja active Active
- 2016-09-30 PT PT212058846T patent/PT4019022T/pt unknown
- 2016-09-30 ES ES16852664T patent/ES2905401T3/es active Active
- 2016-09-30 MA MA43052A patent/MA43052B1/fr unknown
- 2016-09-30 EP EP16852664.8A patent/EP3355890B1/fr active Active
- 2016-09-30 HR HRP20220059TT patent/HRP20220059T1/hr unknown
- 2016-09-30 TW TW110123218A patent/TWI796714B/zh active
- 2016-09-30 LT LTEPPCT/US2016/054619T patent/LT3355890T/lt unknown
- 2016-09-30 SI SI201631448T patent/SI3355890T1/sl unknown
- 2016-09-30 AU AU2016330926A patent/AU2016330926B2/en active Active
- 2016-09-30 LT LTEP21205884.6T patent/LT4019022T/lt unknown
- 2016-09-30 CN CN202210213842.XA patent/CN114591212A/zh active Pending
- 2016-09-30 DK DK16852664.8T patent/DK3355890T3/da active
- 2016-09-30 RS RS20220035A patent/RS62807B1/sr unknown
- 2016-09-30 MX MX2018003930A patent/MX2018003930A/es unknown
- 2016-09-30 PT PT168526648T patent/PT3355890T/pt unknown
- 2016-09-30 MY MYPI2018000405A patent/MY198346A/en unknown
- 2016-09-30 HU HUE16852664A patent/HUE057106T2/hu unknown
- 2016-09-30 MD MDE20180777T patent/MD3355890T2/ro unknown
-
2018
- 2018-03-14 IL IL258104A patent/IL258104B/en active IP Right Grant
- 2018-03-27 PH PH12018500678A patent/PH12018500678A1/en unknown
- 2018-03-28 MX MX2021010297A patent/MX2021010297A/es unknown
- 2018-04-27 CO CONC2018/0004572A patent/CO2018004572A2/es unknown
- 2018-11-01 HK HK18113965.4A patent/HK1254865A1/zh unknown
-
2019
- 2019-12-18 US US16/718,537 patent/US11066360B2/en active Active
-
2021
- 2021-02-24 IL IL281066A patent/IL281066B/en unknown
- 2021-03-26 AU AU2021201924A patent/AU2021201924B2/en active Active
- 2021-07-13 US US17/374,335 patent/US11807605B2/en active Active
- 2021-07-15 JP JP2021117361A patent/JP7431778B2/ja active Active
-
2022
- 2022-01-13 CY CY20221100030T patent/CY1124907T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
TN2015000391A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
MY195194A (en) | Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors | |
MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
EA202090052A1 (ru) | Содержащие имидазол ингибиторы alk2 киназы | |
MA38315A1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
MA51627B1 (fr) | Benzofurane, benzopyrrole, benzothiophène substitués et inhibiteurs du complément structurellement apparentés | |
EA202192433A1 (ru) | Соединения, полезные в терапии вич | |
EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k | |
PH12021550304A1 (en) | Novel medicament for treating inflammatory bowel disease | |
PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
MA39253B1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
MA35010B1 (fr) | Inhibiteurs de la peptide déformylase | |
MA39719B1 (fr) | Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
FR3028762B1 (fr) | Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine | |
MA52370B1 (fr) | Dérivés de la pyridine et leurs utilisations thérapeutiques comme inhibiteurs du trpc6 | |
EA202091668A3 (ru) | Ингибиторы калликреина плазмы человека | |
FR3042191B1 (fr) | Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives |